Nuvelo Acquires Alfimeprase Rights from Amgen
By Business Review Editor
Pharma Deals Review: Vol 2004 Issue 54 (Table of Contents)
Published: 4 Dec-2004
DOI: 10.3833/pdr.v2004.i54.750 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Nuvelo acquired the worldwide rights to develop and commercialize its lead product, the thrombolytic agent alfimeprase from Amgen in return for payment of previously negotiated milestones and royalties...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS